Overexpression of MiR-155 in Clear-cell Renal Cell Carcinoma and Its Oncogenic Effect Through Targeting FOXO3a

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2017 Jun 2

PMID 28565840

Citations 26

Authors

Hong Ji

Dong Tian

Bing Zhang

Yangyang Zhang

Dongliang Yan

Shuhua Wu

Affiliations

Soon will be listed here.

Abstract

MicroRNA-155 (miR-155) is overexpressed in numerous human cancer types and has an oncogenic role. Previous study has revealed that miR-155 serves an important role in the progression of clear-cell renal cell carcinoma (ccRCC); however, the underlying mechanism was not completely clarified. The present study aimed to investigate the biological role of miR-155 in ccRCC and the underlying molecular mechanisms. The expression of miR-155 in 20 ccRCC and adjacent normal kidney tissues was determined by PCR. After downregulation of miR-155 expression by miR-155 inhibitor, cell growth was assessed by MTT and colony formation assays. Apoptosis and cell cycle distribution were analyzed by flow cytometry. Cell invasion and migration was detected by wound healing and Transwell assays. Furthermore, forkhead box O3a (FOXO3a) mRNA and protein expression were detected by PCR and immunoblotting. The expression of FOXO3a in 20 ccRCC tissues was also examined by immunohistochemistry. The expression of miR-155 was upregulated in ccRCC tissues compared to that in adjacent normal tissues. Inhibition of miR-155 significantly suppressed the proliferation, colony formation, migration and invasion, and induced G1 arrest and apoptosis of ccRCC cells . Moreover, inhibition of miR-155 significantly upregulated FOXO3a expression, and miR-155 expression was inversely correlated with FOXO3a expression in ccRCC tissues. In conclusion, miR-155 may have an important role in the genesis of ccRCC through targeting FOXO3a and may be a potential target for ccRCC therapy.

Citing Articles

Shikonin Causes an Apoptotic Effect on Human Kidney Cancer Cells through Ras/MAPK and PI3K/AKT Pathways.

Kiraly J, Szabo E, Fodor P, Fejes Z, Nagy Jr B, Juhasz E Molecules. 2023; 28(18).

PMID: 37764501 PMC: 10534756. DOI: 10.3390/molecules28186725.

Identification of microRNA editing sites in clear cell renal cell carcinoma.

Liu Y, Guo S, Xie W, Yang H, Li W, Zhou N Sci Rep. 2023; 13(1):15117.

PMID: 37704698 PMC: 10499803. DOI: 10.1038/s41598-023-42302-y.

The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis.

Wu Y, Hong Q, Lu F, Zhang Z, Li J, Nie Z Mol Diagn Ther. 2023; 27(3):283-301.

PMID: 36939982 DOI: 10.1007/s40291-023-00641-6.

Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy.

Rustum Y, Reis R, Rustum T Int J Mol Sci. 2023; 24(2).

PMID: 36674417 PMC: 9864911. DOI: 10.3390/ijms24020902.

SNHG5 promotes proliferation and induces apoptosis in melanoma by sponging miR-155.

Yan L, Wang S, Li Y, Tognetti L, Tan R, Zeng K RSC Adv. 2022; 8(11):6160-6168.

PMID: 35539582 PMC: 9078272. DOI: 10.1039/c7ra12520h.

References

Li M, Wang Y, Song Y, Bu R, Yin B, Fei X . MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review). Oncol Rep. 2015; 33(4):1571-8. PMC: 4358077. DOI: 10.3892/or.2015.3799. View

Calvo E, Schmidinger M, Heng D, Grunwald V, Escudier B . Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev. 2016; 50:109-117. DOI: 10.1016/j.ctrv.2016.09.002. View

Cohen H, McGovern F . Renal-cell carcinoma. N Engl J Med. 2005; 353(23):2477-90. DOI: 10.1056/NEJMra043172. View

Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R . miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res. 2014; 74(15):4145-56. DOI: 10.1158/0008-5472.CAN-13-2038. View

Bouamar H, Jiang D, Wang L, Lin A, Ortega M, Aguiar R . MicroRNA 155 control of p53 activity is context dependent and mediated by Aicda and Socs1. Mol Cell Biol. 2015; 35(8):1329-40. PMC: 4372698. DOI: 10.1128/MCB.01446-14. View

Cai Z, Chen Q, Chen Y, Gu M, Zheng D, Zhou J . microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7. Mol Med Rep. 2014; 11(1):533-8. DOI: 10.3892/mmr.2014.2744. View

Kong W, He L, Coppola M, Guo J, Esposito N, Coppola D . MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010; 285(23):17869-79. PMC: 2878550. DOI: 10.1074/jbc.M110.101055. View

Lao G, Liu P, Wu Q, Zhang W, Liu Y, Yang L . Mir-155 promotes cervical cancer cell proliferation through suppression of its target gene LKB1. Tumour Biol. 2014; 35(12):11933-8. DOI: 10.1007/s13277-014-2479-7. View

Sunters A, Fernandez de Mattos S, Stahl M, Brosens J, Zoumpoulidou G, Saunders C . FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 2003; 278(50):49795-805. DOI: 10.1074/jbc.M309523200. View

10.

Tili E, Croce C, Michaille J . miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol. 2009; 28(5):264-84. DOI: 10.1080/08830180903093796. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Juan D, Alexe G, Antes T, Liu H, Madabhushi A, DeLisi C . Identification of a microRNA panel for clear-cell kidney cancer. Urology. 2009; 75(4):835-41. DOI: 10.1016/j.urology.2009.10.033. View

13.

Anderson M, Viars C, Czekay S, Cavenee W, Arden K . Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics. 1998; 47(2):187-99. DOI: 10.1006/geno.1997.5122. View

14.

Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang H . microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol Rep. 2013; 30(5):2111-8. DOI: 10.3892/or.2013.2685. View

15.

Tran H, Brunet A, Grenier J, Datta S, Fornace Jr A, DiStefano P . DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science. 2002; 296(5567):530-4. DOI: 10.1126/science.1068712. View

16.

Cummins J, Velculescu V . Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006; 25(46):6220-7. DOI: 10.1038/sj.onc.1209914. View

17.

Ge Y, Wu R, Xin H, Zhu M, Lu T, Liu H . A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2015; 141(7):1291-9. DOI: 10.1007/s00432-015-1927-0. View

18.

Li T, Yang J, Lv X, Liu K, Gao C, Xing Y . miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2. Biotechnol Lett. 2014; 36(9):1743-52. DOI: 10.1007/s10529-014-1540-3. View

19.

Spinetti G, Cordella D, Fortunato O, Sangalli E, Losa S, Gotti A . Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res. 2012; 112(3):510-22. PMC: 3616365. DOI: 10.1161/CIRCRESAHA.112.300598. View

20.

Thai T, Calado D, Casola S, Ansel K, Xiao C, Xue Y . Regulation of the germinal center response by microRNA-155. Science. 2007; 316(5824):604-8. DOI: 10.1126/science.1141229. View